Fig. 4

CT images of representative cases. A Patient 2 experienced pseudo-progression after 4 cycles of GT90001 plus nivolumab treatment and achieved partial response at cycle 6. B Patient 6 with lung metastases achieved stable disease under treatment while also experiencing progressive enlargement of lung lesions in February 2020. After surgical resection for lung lesions in November 2020, the patient remained recurrence-free for more than 6 months. C Patient 1 with lung metastases achieved PR under the treatment but experienced HCC recurrence